The Fred Hutchinson/University of Washington Cancer Consortium (Consortium), formed in 2002, is a partnership of: Fred Hutchinson Cancer Research Center, an NCI-designated Comprehensive Cancer Center since 1976 and a CCSG grant recipient since 1973;the University of Washington;and Children's Hospital and Regional Medical Center. The Consortium brings together more than 400 faculty with research interests in basic, clinical and public health sciences related to cancer, with total NCI funding of $73 million (direct costs). The goal of the Consortium is the elimination of cancer through more effective prevention, diagnostics, and treatment, deriving from fundamental insights into the biology of the disease. The extensive interdisciplinary collaboration between the three institutions in the cancer research disciplines of basic, clinical, and public health sciences affords new opportunities to reduce suffering and mortality from cancer. The Consortium faculty are organized into 13 productive research programs with emphasis in the Public Health (Biostatistics, Epidemiology, Cancer Prevention), Clinical (Transplantation Biology and Clinical Transplantation), and Fundamental sciences (Basic Sciences, Stem/Progenitor Cell Biology, Genome Instability &Mutagenesis), as well as programs that are highly cross-disciplinary (Women's Cancer;Prostate Cancer;Gl Cancer Etiology, Prevention, &Early Detection;Cancer Imaging;and Immunology &Vaccine Development). During the next grant period the Consortium will seek to: (1) Strengthen its clinical research programs and infrastructure to permit more rapid development of diagnostics and therapeutics;(2) Strengthen its presence in genetic/genomics;(3) Strengthen its presence in computational biology;(4) Continue its commitment to early cancer detection, including protein biomarker discovery and molecular diagnostics;(5) Build on leadership in research on infectious diseases and virology and develop a program focusing on infectious agents and cancer;(6) Continue to recruit promising laboratory scientists in broad areas of basic biology;and (7) Continue to encourage and support a focus on aging for relevant programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA015704-39S4
Application #
8719234
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-01-01
Project End
2013-12-31
Budget Start
2013-01-01
Budget End
2013-12-31
Support Year
39
Fiscal Year
2013
Total Cost
$50,000
Indirect Cost
$21,591
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Morris, S M; Carter, K T; Baek, J Y et al. (2015) TGF-? signaling alters the pattern of liver tumorigenesis induced by Pten inactivation. Oncogene 34:3273-82
Briant, Katherine Josa; Espinoza, Noah; Galvan, Avigail et al. (2015) An innovative strategy to reach the underserved for colorectal cancer screening. J Cancer Educ 30:237-43
Toledo, Chad M; Herman, Jacob A; Olsen, Jonathan B et al. (2014) BuGZ is required for Bub3 stability, Bub1 kinetochore function, and chromosome alignment. Dev Cell 28:282-94
Klippel, Z K; Chou, J; Towlerton, A M et al. (2014) Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC. Gene Ther 21:337-42
Mielcarek, Marco; Kirkorian, Anna Yasmine; Hackman, Robert C et al. (2014) Langerhans cell homeostasis and turnover after nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation. Transplantation 98:563-8
Luo, Yanxin; Wong, Chao-Jen; Kaz, Andrew M et al. (2014) Differences in DNA methylation signatures reveal multiple pathways of progression from adenoma to colorectal cancer. Gastroenterology 147:418-29.e8
Cermelli, Silvia; Jang, In Sock; Bernard, Brady et al. (2014) Synthetic lethal screens as a means to understand and treat MYC-driven cancers. Cold Spring Harb Perspect Med 4:
Rizzardi, Anthony E; Rosener, Nikolaus K; Koopmeiners, Joseph S et al. (2014) Evaluation of protein biomarkers of prostate cancer aggressiveness. BMC Cancer 14:244
Vainstein, V; Buckley, S A; Shukron, O et al. (2014) Rapid rate of peripheral blood blast clearance accurately predicts complete remission in acute myeloid leukemia. Leukemia 28:713-6
Laszlo, George S; Ries, Rhonda E; Gudgeon, Chelsea J et al. (2014) High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Leuk Lymphoma 55:2817-21

Showing the most recent 10 out of 300 publications